Senate health committee narrows pharmacy compounding labeling rules after stakeholder concerns

BOISE, Idaho — The Senate Health and Welfare Committee on Wednesday approved a rewrite of the Idaho State Board of Pharmacy’s rule chapter while removing three subsections governing distribution labeling for compounded products, after testimony and late stakeholder outreach raised questions about how state rules would interact with a still-draft federal Food and Drug Administration guidance.

The committee voted to let a set of temporary pharmacy rules expire without action and then approved the board’s pending rule docket (IDAPA 24.36.01 — pending docket 24-3601-2402) with the committee’s amendment striking subsections listed as 214 E i and ii. Senator Lenny offered the successful substitute motion to remove those subsections; the motion passed on a committee roll call, with the chair announcing the motion passed and later the committee recording the vote as seven in favor and two opposed.

The changes come after the Idaho State Board of Pharmacy completed a ZBR (zero-based regulation) rewrite that removed duplicative statutory language and reorganized the chapter into sections on legal authority, scope, definitions, licensure, practice standards, discipline, fees, compounding and prescription drug monitoring. Nikki Chopsky, bureau chief of health professions for the Division of Occupational and Professional Licenses and executive officer for the Idaho State Board of Pharmacy, told the committee the board had held multiple public meetings and included representatives of both state pharmacy associations and individual practitioners in drafting the pending rules.

"The board stands committed to working transparently with these stakeholders and others for a workable solution in an environment that is unsettled at this time," Chopsky said, describing late stakeholder concerns about compounding labeling and distribution language that had been moved into the pending chapter.

Chopsky explained the board did not incorporate the FDA draft guidance by reference, noting that the FDA document is marked draft and nonbinding. "The draft guidance document of the FDA is clearly marked draft, not for implementation and contains non binding recommendations," she said, adding that the board preferred to rely on Idaho law and the board’s own compounding framework until federal guidance is finalized.

Senator Lenny said he was concerned Idaho might be stricter than other states and that strict state enforcement while the FDA guidance remains draft could impede access and raise costs. "It seems like Idaho is the teacher saying, I know the principal said we can have snacks on campus, but we're gonna enforce this no snack rule," Lenny said, using an analogy to describe the perceived tension between federal draft guidance and Idaho’s rules.

Senator Wintrow urged caution on matters involving drug safety. "When we're talking about drugs, and we haven't had this document finalized, that it's maybe best to leave that in rule, and then have a more lengthy discussion with the folks who came out late," she said, adding concern about health and safety risks if regulatory gaps emerged.

Chopsky told the committee that Idaho has multiple legal pathways for compounded products to reach patients and noted there are both 503A (pharmacy) and 503B (outsourced manufacturer) entities that operate under different federal standards. She said the board retained the labeling language that had been reviewed by the legislature since 2015 but was prepared to work with stakeholders if federal requirements change.

Votes at a glance - Temporary docket 24-3601-2401 (pharmacy temporary rules): Motion to take no action (mover: Senator Harris; second: Senator Wintrow). Outcome: take no action (voice vote). - Pending docket 24-3601-2402 (Idaho State Board of Pharmacy rewrite): Substitute motion (mover: Senator Lenny; second: Senator Seiderfeld) to approve pending rules while striking subsections 214 E i and ii. Outcome: motion passed; recorded on the floor as approved with exception (committee announced result as 7 yes, 2 no).

Why it matters The committee’s change preserves the board’s overall overhaul of pharmacy rules but narrows a specific compounding/distribution labeling provision after industry stakeholders signaled late concerns. The action maintains Idaho’s existing statutory and regulatory framework while leaving space for further stakeholder negotiation if federal guidance or litigation alters the legal landscape.

Background and supporting details Chopsky said the board made more than 35 changes to the chapter during the ZBR review, consolidating definitions, removing statutory duplications, and moving fee tables and licensure requirements where statute now governs those items. Key procedural notes in the rewrite included: - Stakeholder engagement: five open public meetings, two negotiated rulemaking hearings and one public hearing; state pharmacy associations and individual practitioners participated (Chopsky said there were sometimes 12–20 people online or in the room during stakeholder sessions). - Inventory and reporting changes: annual inventory requirements were replaced by biannual inventory for federal alignment; reporting of criminal convictions was changed to a 30-day reporting requirement; prescription drug monitoring reporting updated to end-of-business-day reporting. - Compounding: prior exemptions for certain radiopharmaceuticals were removed; the board moved toward a "standard of care" approach for some compounding subsections.

What the committee decided to do next Committee members directed staff and the board to continue stakeholder engagement on compounding labeling and distribution pathways. The committee approved the pending rule chapter with the narrower labeling language removed and allowed the temporary rules to expire.

Next steps If federal rules or court decisions change the legal landscape for compounding, the board and the committee can revisit the rules through the regular ZBR and rulemaking processes.

Ending The committee completed its pharmacy rule review and moved on to other health professions dockets; committee leadership said they would continue consideration of related regulatory dockets in upcoming meetings.